A white-knuckle ride of open COVID drug discovery

Nature. 2021 Jun;594(7863):330-332. doi: 10.1038/d41586-021-01571-1.
No abstract available

Keywords: Drug discovery; Medical research; Research management; SARS-CoV-2.

MeSH terms

  • Animals
  • Antiviral Agents / analysis*
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • COVID-19 / epidemiology
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Clinical Trials as Topic
  • Cooperative Behavior*
  • Coronavirus 3C Proteases / antagonists & inhibitors
  • Coronavirus 3C Proteases / chemistry
  • Crowdsourcing
  • Crystallography, X-Ray / instrumentation
  • Drug Discovery / methods*
  • Drug Discovery / organization & administration*
  • Drug Evaluation, Preclinical / methods*
  • Drug Repositioning
  • Goals
  • Humans
  • International Cooperation
  • Israel / epidemiology
  • Open Access Publishing*
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / isolation & purification
  • Social Media
  • Synchrotrons
  • Time Factors
  • United Kingdom / epidemiology
  • Videoconferencing
  • Volunteers
  • World Health Organization / organization & administration

Substances

  • Antiviral Agents
  • 3C-like proteinase, SARS-CoV-2
  • Coronavirus 3C Proteases